Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BeOne Medicines Ltd. - American Depositary Shares
(NQ:
ONC
)
361.65
+3.58 (+1.00%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about BeOne Medicines Ltd. - American Depositary Shares
< Previous
1
2
3
Next >
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
September 01, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
August 31, 2026
From
BeOne Medicines, Ltd.
Via
Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
August 31, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
August 25, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
August 18, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 10, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
August 05, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
July 23, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
July 17, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
June 30, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
June 12, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
June 11, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
June 01, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
May 29, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
May 27, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
May 21, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
May 20, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
May 13, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
May 06, 2026
From
BeOne Medicines Ltd
Via
Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
April 29, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
April 22, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
February 26, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Present at Upcoming Investor Conferences
February 17, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
February 11, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
January 06, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 23, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
December 18, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
December 08, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
